Ichiro Sakanoue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ichiro Sakanoue has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Yutaka Takahashi
Department of Thoracic Surgery, Kobe City Medical Center General Hospital, Kobe, Japan
8 shared publicationsHiroshi Hamakawa
Department of Thoracic Surgery, Kobe City Medical Center General Hospital, Kobe, Japan
7 shared publicationsDaisuke Nakajima
5 shared publications- Satona Tanaka
Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
5 shared publications Yukihiro Imai
Department of Clinical Pathology, Kobe City Medical Center General Hospital, Kobe, Japan
5 shared publications- Hidenao Kayawake
Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan
4 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Elsevier in SSRN Electronic Journal
Residual risk of local recurrence after segmentectomy for stage I non-small-cell lung cancer
BackgroundLocal recurrence remains the principal oncological concern after segmentectomy. We examined its incidence, and where residual risk persists, in a cohort managed under a standardized technical framework of routine three-dimensional planning, selective preoperative tumor localization and intersegmental plane demarcation.Patients and MethodsWe retrospectively studied 517 consecutive patients who underwent anatomical segmentectomy for clinical stage I non-small-cell lung cancer at a single center between January 2011 and August 2022. All resections included individual division of the segmental artery and bronchus. Local recurrence was defined as relapse at or adjacent to the intersegmental staple line, and its cumulative incidence was estimated by the Kaplan-Meier method. Associations were tested with Mann-Whitney U and Fisher exact tests.ResultsOver a median follow-up of 63 months (interquartile range 50-91.5), local recurrence occurred in 10 patients, with a 5-year cumulative incidence of 1.7% (95% confidence interval 0.5-2.9). Consolidation size, consolidation-to-tumor ratio, central location (each P = 0.01) and a compromised indication (P = 0.03) were associated with local recurrence. Recurrence was concentrated in solid-dominant tumors resected for compromised indications (6 of 102, 5.9%) compared with all other strata (4 of 415, 1.0%; P = 0.005). Rates did not differ across the three demarcation techniques (P = 1.00) or by localization (P = 0.51).ConclusionUnder a standardized technical framework, local recurrence after segmentectomy was infrequent, but residual risk was concentrated almost entirely in solid-dominant tumors resected for compromised indications, in whom a wider parenchymal margin or extension to an adjacent segment should be considered.
- 8 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessResidual risk of local recurrence after segmentectomy for stage I non-small-cell lung cancer
BackgroundLocal recurrence remains the principal oncological concern after segmentectomy. We examined its incidence, and where residual risk persists, in a cohort managed under a standardized technical framework of routine three-dimensional planning, selective preoperative tumor localization and intersegmental plane demarcation.Patients and MethodsWe retrospectively studied 517 consecutive patients who underwent anatomical segmentectomy for clinical stage I non-small-cell lung cancer at a single center between January 2011 and August 2022. All resections included individual division of the segmental artery and bronchus. Local recurrence was defined as relapse at or adjacent to the intersegmental staple line, and its cumulative incidence was estimated by the Kaplan-Meier method. Associations were tested with Mann-Whitney U and Fisher exact tests.ResultsOver a median follow-up of 63 months (interquartile range 50-91.5), local recurrence occurred in 10 patients, with a 5-year cumulative incidence of 1.7% (95% confidence interval 0.5-2.9). Consolidation size, consolidation-to-tumor ratio, central location (each P = 0.01) and a compromised indication (P = 0.03) were associated with local recurrence. Recurrence was concentrated in solid-dominant tumors resected for compromised indications (6 of 102, 5.9%) compared with all other strata (4 of 415, 1.0%; P = 0.005). Rates did not differ across the three demarcation techniques (P = 1.00) or by localization (P = 0.51).ConclusionUnder a standardized technical framework, local recurrence after segmentectomy was infrequent, but residual risk was concentrated almost entirely in solid-dominant tumors resected for compromised indications, in whom a wider parenchymal margin or extension to an adjacent segment should be considered.
- Open Access
- 18 August 2026
- Published by Elsevier in JTCVS Open
- Vol. 33
Living-donor lung transplantation for patients on extracorporeal membrane oxygenation support: A case series
- 18 August 2026
- Published by Elsevier in JTCVS Open
- Vol. 33
Open AccessLiving-donor lung transplantation for patients on extracorporeal membrane oxygenation support: A case series
- 8 July 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (5) , 101478
Donor selection in living-donor lung transplantation for familial pulmonary fibrosis: A narrative review and single-center practical approach
- 8 July 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (5) , 101478
Donor selection in living-donor lung transplantation for familial pulmonary fibrosis: A narrative review and single-center practical approach
- Open Access
- 17 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2331
Endothelial C-type natriuretic peptide/guanylyl cyclase-B signaling prevents pulmonary arterial hypertension
C-type natriuretic peptide (CNP) is released from endothelial cells and acts as an autocrine/paracrine mediator, regulating systemic blood pressure and vascular remodeling via guanylyl cyclase-B (GC-B) and natriuretic peptide receptor-C. We investigate the impact of vascular CNP/GC-B signaling on the development of pulmonary arterial hypertension (PAH). Mice developing pulmonary hypertension (PH) show reduced pulmonary NPPC and NPR2 expression than mice without PH. S imilarly, endothelial cells (EC) from patients with idiopathic PAH exhibit lower NPPC and NPR2 expression than control EC. EC-specific CNP or GC-B conditional knockout (CNP ecKO or GC-B ecKO) mice, but not smooth muscle cell-specific GC-B conditional knockout (GC-B smcKO) mice, show more severe PH and greater expression of Edn1, Il6, Ccl2 and Tgfb1 mRNAs than their genetic controls in PAH models. CNP suppresses hypoxia-induced increases in expression of these mRNAs and restored SMAD2/3-SMAD1/5/9 balance in cultured human pulmonary arterial EC. Moreover, CNP administration prevents PH in genetic control and GC-B-smcKO mice but not in GC-B ecKO mice. CNP administration also has therapeutic effects against Sugen5416-hypoxia PAH models as well as additive benefits with established therapies. Endothelial CNP/GC-B signaling thus exerts pivotal preventative effects against development of PH, suggesting the therapeutic potential of CNP for PAH.
- 17 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2331
Open AccessEndothelial C-type natriuretic peptide/guanylyl cyclase-B signaling prevents pulmonary arterial hypertension
C-type natriuretic peptide (CNP) is released from endothelial cells and acts as an autocrine/paracrine mediator, regulating systemic blood pressure and vascular remodeling via guanylyl cyclase-B (GC-B) and natriuretic peptide receptor-C. We investigate the impact of vascular CNP/GC-B signaling on the development of pulmonary arterial hypertension (PAH). Mice developing pulmonary hypertension (PH) show reduced pulmonary NPPC and NPR2 expression than mice without PH. S imilarly, endothelial cells (EC) from patients with idiopathic PAH exhibit lower NPPC and NPR2 expression than control EC. EC-specific CNP or GC-B conditional knockout (CNP ecKO or GC-B ecKO) mice, but not smooth muscle cell-specific GC-B conditional knockout (GC-B smcKO) mice, show more severe PH and greater expression of Edn1, Il6, Ccl2 and Tgfb1 mRNAs than their genetic controls in PAH models. CNP suppresses hypoxia-induced increases in expression of these mRNAs and restored SMAD2/3-SMAD1/5/9 balance in cultured human pulmonary arterial EC. Moreover, CNP administration prevents PH in genetic control and GC-B-smcKO mice but not in GC-B ecKO mice. CNP administration also has therapeutic effects against Sugen5416-hypoxia PAH models as well as additive benefits with established therapies. Endothelial CNP/GC-B signaling thus exerts pivotal preventative effects against development of PH, suggesting the therapeutic potential of CNP for PAH.
- Open Access
- 1 January 2026
- Published by Editorial Committee of Annals of Thoracic and Cardiovascular Surgery in Annals of Thoracic and Cardiovascular Surgery
- Vol. 32 (1)
Pericardial Closure Using Donor Pericardium in Deceased-Donor Lung Transplantation
Purpose: The optimal method of pericardial closure in lung transplantation remains controversial. This study aimed to evaluate the technical feasibility and procedural simplicity of pericardial closure using donor pericardium.Methods: We retrospectively reviewed 70 adult patients who underwent deceased-donor bilateral lung transplantation with cardiopulmonary bypass or central extracorporeal membrane oxygenation between December 2010 and January 2024 at Kyoto University Hospital. Patients were divided into the Donor pericardium group (n = 21) and the Autologous tissue group (n = 49). Pericardial closure time was assessed as an indicator of procedural simplicity, and postoperative complications within 1 year were descriptively evaluated.Results: Baseline characteristics did not differ between the groups. Mean pericardial closure time was significantly shorter in the Donor pericardium group than in the Autologous tissue group (13 ± 2.4 vs 19 ± 1.6 min, P = 0.03). No clinically concerning differences in postoperative complications were observed during short- to mid-term follow-up.Conclusion: Pericardial closure using donor pericardium enables technically simpler and faster closure without apparent short-term safety concerns.
- 1 January 2026
- Published by Editorial Committee of Annals of Thoracic and Cardiovascular Surgery in Annals of Thoracic and Cardiovascular Surgery
- Vol. 32 (1)
Open AccessPericardial Closure Using Donor Pericardium in Deceased-Donor Lung Transplantation
Purpose: The optimal method of pericardial closure in lung transplantation remains controversial. This study aimed to evaluate the technical feasibility and procedural simplicity of pericardial closure using donor pericardium.Methods: We retrospectively reviewed 70 adult patients who underwent deceased-donor bilateral lung transplantation with cardiopulmonary bypass or central extracorporeal membrane oxygenation between December 2010 and January 2024 at Kyoto University Hospital. Patients were divided into the Donor pericardium group (n = 21) and the Autologous tissue group (n = 49). Pericardial closure time was assessed as an indicator of procedural simplicity, and postoperative complications within 1 year were descriptively evaluated.Results: Baseline characteristics did not differ between the groups. Mean pericardial closure time was significantly shorter in the Donor pericardium group than in the Autologous tissue group (13 ± 2.4 vs 19 ± 1.6 min, P = 0.03). No clinically concerning differences in postoperative complications were observed during short- to mid-term follow-up.Conclusion: Pericardial closure using donor pericardium enables technically simpler and faster closure without apparent short-term safety concerns.
- 9 September 2024
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 73 (01) , 086-089
Pulmonary Metastasectomy after Immune Checkpoint Inhibitors in Renal Cell Carcinoma
The management of oligometastatic renal cell carcinoma with pulmonary metastases is controversial and occasionally requires multimodality management, including salvage pulmonary metastasectomy after immune checkpoint inhibitors (ICIs). However, limited data are available on these patients. We describe a case series of three consecutive patients who underwent salvage pulmonary metastasectomy after ICIs for oligometastatic renal cell carcinoma and discussed the important characteristics of these patients. After salvage pulmonary metastasectomy, none of the patients had recurrent pulmonary metastases, although one of them developed a brain metastasis postoperatively. Our case series suggests that salvage pulmonary metastasectomy after ICIs may control pulmonary metastases in carefully selected patients with oligometastatic renal cell carcinoma, although the management of extrapulmonary metastases may be required after salvage pulmonary metastasectomy.
- 9 September 2024
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 73 (01) , 086-089
Pulmonary Metastasectomy after Immune Checkpoint Inhibitors in Renal Cell Carcinoma
The management of oligometastatic renal cell carcinoma with pulmonary metastases is controversial and occasionally requires multimodality management, including salvage pulmonary metastasectomy after immune checkpoint inhibitors (ICIs). However, limited data are available on these patients. We describe a case series of three consecutive patients who underwent salvage pulmonary metastasectomy after ICIs for oligometastatic renal cell carcinoma and discussed the important characteristics of these patients. After salvage pulmonary metastasectomy, none of the patients had recurrent pulmonary metastases, although one of them developed a brain metastasis postoperatively. Our case series suggests that salvage pulmonary metastasectomy after ICIs may control pulmonary metastases in carefully selected patients with oligometastatic renal cell carcinoma, although the management of extrapulmonary metastases may be required after salvage pulmonary metastasectomy.
- 27 June 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (12) , 2008-2017
Real-time lung weight measurement during clinical ex vivo lung perfusion
- 27 June 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (12) , 2008-2017
Real-time lung weight measurement during clinical ex vivo lung perfusion
- 19 February 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (6) , 818-828
Clinical significance of donor lung weight at procurement and during ex vivo lung perfusion
- 19 February 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (6) , 818-828
Clinical significance of donor lung weight at procurement and during ex vivo lung perfusion
- Open Access
- 1 April 2021
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 40 (4) , S69-S70
Real-Time Lung Weight Measurement during Ex Vivo Lung Perfusion: Clinical Importance of Early Weight Gain
- 1 April 2021
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 40 (4) , S69-S70
Open AccessReal-Time Lung Weight Measurement during Ex Vivo Lung Perfusion: Clinical Importance of Early Weight Gain